Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.70 |
| ▸ | TSHR | P16473 | 6/20 | 0.52 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.52 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | GPR84 | Q9NQS5 | 7/20 | 0.48 |
| ▸ | PPARG | P37231 | 7/20 | 0.48 |
| ▸ | PPARD | Q03181 | 7/20 | 0.48 |
| ▸ | PPARA | Q07869 | 7/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 5/20 | 0.48 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.48 |
| ▸ | TLR2 | O60603 | 2/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.48 |
| ▸ | FABP4 | P15090 | 2/20 | 0.48 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.48 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | PDE4A | P27815 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14809715 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL3504230 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL3505211 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL14809726 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL14809112 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL14809412 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL3504682 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL14809980 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL14809593 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 | |
| SCHEMBL29032818 | 1.00 | LMNA (0.70) | LMNATSHRNFKB1PMP22ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 234 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250215299-A1 | NOVEL CRYOGENIC COMPOSITION | LESAGE PATRICK (FR) | 2025-07-03 | — | — | US | claimed |
| EP-4499002-A1 | NOVEL CRYOGENIC COMPOSITION | Lesage, Patrick (FR) | 2025-02-05 | — | — | EP | claimed |
| EP-3601429-B1 | ETHYL CELLULOSE FILMS, PREPARATION OF SAME AND DOUBLE-BASE PROPELLANT BLOCKS COMBUSTION-INHIBITED WITH SUCH FILMS | EURENCO FRANCE SAS (FR) | 2024-11-27 | — | — | EP | claimed |
| WO-2023180665-A1 | NOVEL CRYOGENIC COMPOSITION | LESAGE PATRICK (FR) | 2023-09-28 | — | — | WO | claimed |
| US-11395823-B2 | Topical administration of MEK inhibiting agents for the treatment of skin disorders | DUKE UNIVERSITY (US) | 2022-07-26 | — | — | US | claimed |
| CN-113710238-A | Transdermal therapeutic system | LTS勒曼治疗系统股份公司 | 2021-11-26 | — | — | CN | claimed |
| US-11013634-B2 | Cryogenic composition | LESAGE PATRICK (FR) | 2021-05-25 | — | — | US | claimed |
| EP-3405544-B1 | CRYOGENIC COMPOSITION | LESAGE PATRICK (FR) | 2021-05-19 | — | — | EP | claimed |
| US-20210060018-A1 | TOPICAL ADMINISTRATION OF MEK INHIBITING AGENTS FOR THE TREATMENT OF SKIN DISORDERS | DUKE UNIVERSITY | 2021-03-04 | — | — | US | claimed |
| EP-3601429-A1 | ETHYL CELLULOSE FILMS, PREPARATION OF SAME AND DOUBLE-BASE PROPELLANT BLOCKS COMBUSTION-INHIBITED WITH SUCH FILMS | Eurenco (FR) | 2020-02-05 | — | — | EP | claimed |
| US-20190076292-A1 | NOVEL CRYOGENIC COMPOSITION | LESAGE PATRICK (FR) | 2019-03-14 | — | — | US | claimed |
| EP-3405544-A1 | CRYOGENIC COMPOSITION | Lesage, Patrick (FR) | 2018-11-28 | — | — | EP | claimed |
| US-20170273945-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | Ziarco Pharma Ltd. (GB) | 2017-09-28 | — | — | US | claimed |
| US-20170007576-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | Ziarco Pharma Ltd. (GB) | 2017-01-12 | — | — | US | claimed |
| EP-3102201-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | Ziarco Pharma Ltd (GB) | 2016-12-14 | — | — | EP | claimed |
| WO-2015118320-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | ZIARCO PHARMA LIMITED (GB) | 2015-08-13 | — | — | WO | claimed |
| CN-101155571-B | Stick solid cosmetic and process for producing the same | SHISEDO CO LTD | 2012-07-18 | — | — | CN | claimed |
| US-8183232-B2 | Therapeutic agent for hemorrhoidal disease | TEIKOKU SEIYAKU CO., LTD. (JP) | 2012-05-22 | — | — | US | claimed |
| CN-122070123-A | Solid powder cosmetic | 高丝控股公司 | 2026-05-19 | — | — | CN | disclosed |
| US-4017615-A | ESPECIALLY USEFUL FOR ANTIINFLAMMATORY TOPICAL CORTICOIDS | SYNTEX CORPORATION (PM) | 1977-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170273945-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | IL17A, IL5, CCL11 | LMNA 4066/4885TSHR 4374/4885NFKB1 36/4885 |
| US-20170007576-A1 | PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION | IL17A, IL5, CCL11 | LMNA 4066/4885TSHR 4374/4885NFKB1 36/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.